Icotrokinra Achieves Primary Endpoint in Phase 3 Psoriatic Arthritis Trial

In the Phase 3 ICONIC-PsA 1 trial, the drug icotrokinra (ICOTYDE) demonstrated a significant ACR20 response at Week 16 in biologic-naive patients with psoriatic arthritis, with 58% of patients receiving icotrokinra achieving the endpoint compared to 41% on placebo. The trial also showed improvements in skin involvement, with 57% of patients on icotrokinra achieving clear or almost clear skin (IGA 0/1) versus 14% on placebo. These results were presented as a late-breaking poster at ACR Convergence 2026.